Part the Cloud Translational Research supports academic investigators and small companies in testing treatments and disease-progression biomarkers to advance Alzheimer’s and related dementia research.
Full application deadlines moved from December 15, 2026 to January 5, 2027, and for ISTAART members from December 17, 2026 to January 7, 2027 (5 p.m. ET). Repurposed-drug study guidance also replaces “pre-symptomatic” with a repeated “symptomatic.”
Funder: Alzheimer's Association
Due Dates: October 20, 2026 (LOI) | October 22, 2026 (ISTAART LOI) | January 5, 2027 (Full application) | January 7, 2027 (ISTAART full application)
Funding Amounts: Up to $1,000,000 per award, including direct and indirect costs, over two to three years
Summary: Supports early-stage human clinical studies advancing novel or repurposed therapeutics and disease-progression biomarkers for Alzheimer’s disease and related dementias.
Key Information: Full applications require an approved current-cycle LOI; applicants must hold full-time Assistant Professor-equivalent or higher positions.
The Alzheimer’s Association’s Part the Cloud Translational Research program supports academic investigators and small companies internationally in moving potential treatments for Alzheimer’s disease and related dementias into early human testing. It addresses the funding gap between preclinical development and larger efficacy trials, supporting Phase 1 studies, pilot proof-of-mechanism studies of agents with established human safety data, and early trials of repurposed drugs.
Studies may assess safety, tolerability, brain penetration, target engagement, or proof of mechanism in people with or without symptomatic or asymptomatic disease. The program also supports proof-of-concept validation of disease-progression biomarkers in clinical trials. Phase 3 studies may qualify depending on scope and scale. Projects must be translational and clearly focused on Alzheimer’s disease or related disorders.